125P A phase IIa study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab (“PAVE”) in advanced non-small cell lung cancer (NSCLC) patients (pts)

PT-112 is an immunogenic small molecule with reported clinical activity. In preclinical models, it induces ICD and synergizes with immune checkpoint inhibitors. Monotherapy and avelumab combination dose escalation studies have shown PT-112 to be well-tolerated. The recommended phase 2 dose was established at 360 mg/m2 (days 1, 8 and 15) when combined with 800 mg of avelumab (days 1 and 15) over a 28-day cycle. Here, we present safety and efficacy findings from the phase 2a PAVE cohort in metastatic NSCLC.